SCHEMBL2480504

SCHEMBL2480504

Nc1nccc(-c2c(-c3cccc(NC(=O)Nc4ccc(C(F)(F)F)cc4)c3)nn3c2SCC3)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 7/20 0.45
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ROCK2 O75116 1/20 0.41
KDR P35968 5/20 0.41
FYN P06241 2/20 0.41
CSF1R P07333 2/20 0.41
KIT P10721 2/20 0.41
FLT1 P17948 2/20 0.41
FLT3 P36888 2/20 0.41
RIPK1 Q13546 1/20 0.41
ABL1 P00519 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
SRC P12931 1/20 0.41
FLT4 P35916 1/20 0.41
BLK P51451 1/20 0.41
BAZ1A Q9NRL2 1/20 0.39
MTOR P42345 1/20 0.39
EPHX2 P34913 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476574 0.88 BRAF (0.46) BRAFCYP2D6CYP2C9KDRBAZ1A
SCHEMBL2480345 0.85 BRAF (0.47) BRAFCYP2D6CYP2C9KDRBAZ1A
SCHEMBL2479886 0.83 BRAF (0.44) BRAFCYP2D6CYP2C9KDRFYN
SCHEMBL2477787 0.81 BRAF (0.46) BRAFCYP2D6CYP2C9ROCK2KDR
SCHEMBL2475882 0.80 BRAF (0.45) BRAFCYP2D6CYP2C9KDRBAZ1A
SCHEMBL2477788 0.78 CNR1 (0.46) BRAFCYP2D6CYP2C9ROCK2
SCHEMBL2479091 0.76 BRAF (0.51) BRAFKDRFYNFLT1FLT3
SCHEMBL12685078 0.76 BRAF (0.49) BRAFCYP2D6CYP2C9ROCK2KDR
SCHEMBL2478417 0.75 BRAF (0.56) BRAFKDR
SCHEMBL1847480 0.75 KDR (0.50) BRAFCYP2D6CYP2C9ROCK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US claimed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP claimed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US claimed
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 BRAF 41/4885CYP2D6 1273/4885CYP2C9 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.